Literature DB >> 12055245

Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells.

Maria L Barilla-LaBarca1, M Kathryn Liszewski, John D Lambris, Dennis Hourcade, John P Atkinson.   

Abstract

C4b and C3b deposited on host cells undergo limited proteolytic cleavage by regulatory proteins. Membrane cofactor protein (MCP; CD46), factor H, and C4b binding protein mediate this reaction, known as cofactor activity, that also requires the plasma serine protease factor I. To explore the roles of the fluid phase regulators vs those expressed on host cells, a model system was used examining complement fragments deposited on cells transfected with human MCP as assessed by FACS and Western blotting. Following incubation with Ab and complement on MCP(+) cells, C4b was progressively cleaved over the first hour to C4d and C4c. There was no detectable cleavage of C4b on MCP(-) cells, indicating that MCP (and not C4BP in the serum) primarily mediates this cofactor activity. C3b deposition was not blocked on MCP(+) cells because classical pathway activation occurred before substantial C4b cleavage. Cleavage, though, of deposited C3b was rapid (<5 min) and iC3b was the dominant fragment on MCP(-) and MCP(+) cells. Studies using a function-blocking mAb further established factor H as the responsible cofactor. If the level of Ab sensitization was reduced 8-fold or if Mg(2+)-EGTA was used to block the classical pathway, MCP efficiently inhibited C3b deposition mediated by the alternative pathway. Thus, for the classical pathway, MCP is the cofactor for C4b cleavage and factor H for C3b cleavage. However, if the alternative pathway mediates C3b deposition, then MCP's cofactor activity is sufficient to restrict complement activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12055245     DOI: 10.4049/jimmunol.168.12.6298

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  Complement system on the attack in autoimmunity.

Authors:  John P Atkinson
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

2.  Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55.

Authors:  Bing Li; Daniel J Allendorf; Richard Hansen; Jose Marroquin; Daniel E Cramer; Claire L Harris; Jun Yan
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 3.  T-cell stimulation and regulation: with complements from CD46.

Authors:  Claudia Kemper; James W Verbsky; Jeffrey D Price; John P Atkinson
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

4.  West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H.

Authors:  Kyung Min Chung; M Kathryn Liszewski; Grant Nybakken; Alan E Davis; R Reid Townsend; Daved H Fremont; John P Atkinson; Michael S Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-28       Impact factor: 11.205

5.  The C-terminus of complement factor H is essential for host cell protection.

Authors:  Mihály Józsi; Martin Oppermann; John D Lambris; Peter F Zipfel
Journal:  Mol Immunol       Date:  2007-01-17       Impact factor: 4.407

Review 6.  Protein engineering to target complement evasion in cancer.

Authors:  Darrick Carter; André Lieber
Journal:  FEBS Lett       Date:  2013-11-14       Impact factor: 4.124

7.  Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.

Authors:  M Kathryn Liszewski; Marilyn K Leung; Richard Hauhart; Celia J Fang; Paula Bertram; John P Atkinson
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

8.  1. Alternative splicing of viral receptors: A review of the diverse morphologies and physiologies of adenoviral receptors.

Authors:  Katherine J D A Excoffon; Jonathan R Bowers; Priyanka Sharma
Journal:  Recent Res Dev Virol       Date:  2014

9.  The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells.

Authors:  Brandon Renner; Kathrin Coleman; Ryan Goldberg; Claudia Amura; Amanda Holland-Neidermyer; Kathryn Pierce; Heather N Orth; Hector Molina; Viviana P Ferreira; Claudio Cortes; Michael K Pangburn; V Michael Holers; Joshua M Thurman
Journal:  J Immunol       Date:  2010-07-30       Impact factor: 5.422

10.  Antagonism of the complement component C4 by flavivirus nonstructural protein NS1.

Authors:  Panisadee Avirutnan; Anja Fuchs; Richard E Hauhart; Pawit Somnuke; Soonjeon Youn; Michael S Diamond; John P Atkinson
Journal:  J Exp Med       Date:  2010-03-22       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.